Published in J Immunol on April 01, 1979
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
B cell differentiation and immunoregulatory T cell function in human cord blood lymphocytes. J Clin Invest (1980) 1.51
Functional 'immaturity' of isolated B cells from patients with hypogammaglobulinaemia. Clin Exp Immunol (1980) 1.45
B cell activation by cytomegalovirus. J Exp Med (1983) 1.24
Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes. Clin Exp Immunol (2012) 1.21
Plasmacytic differentiation of circulating Epstein-Barr virus-infected B lymphocytes during acute infectious mononucleosis. J Exp Med (1981) 1.17
Spectrum of immunodeficiencies with Hodgkin's disease. J Clin Invest (1980) 1.05
Staphylococcal peptidoglycan: T-cell-dependent mitogen and relatively T-cell-independent polyclonal B-cell activator of human lymphocytes. Infect Immun (1983) 0.95
Human monoclonal antibodies against Mycobacterium leprae. Infect Immun (1985) 0.89
Skin test reactivity and in vitro responses to microbes and microbial antigens. Clin Exp Immunol (1980) 0.89
Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line. J Exp Med (1981) 0.87
Immunological features of psoriasis. Effects of Ro-109359, concanavalin A, pokeweed mitogen, and methotrexate on cultivated lymphocytes. Arch Dermatol Res (1981) 0.79
Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis. Ann Rheum Dis (1986) 0.78
Analysis of CD3 antigen expression in patients with ataxia-telangiectasia. Clin Exp Immunol (1987) 0.78
Defective immunoglobulin secretion in response to pokeweed mitogen in sarcoidosis. Clin Exp Immunol (1982) 0.75
Induction of antibody to foot-and-mouth disease virus in presensitized mouse spleen cell cultures. J Virol (1984) 0.75
Effects of interferons on human B-cell differentiation in vitro. Korean J Intern Med (1987) 0.75
The sequence of the human genome. Science (2001) 101.55
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Molecular targets for AIDS therapy. Science (1990) 4.28
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med (1998) 3.95
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1991) 3.69
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol (1992) 2.94
The immunobiology of zinc. Immunol Today (1997) 2.93
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res (1993) 2.74
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1976) 2.65
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet (1968) 2.61
High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr (1994) 2.39
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 2.39
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med (1985) 2.25
Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med (1979) 2.21
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
Fraud in breast-cancer trials. N Engl J Med (1994) 2.16
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A (1992) 2.09
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 2.09
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med (1981) 2.05
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. Blood (1990) 2.02
Isolation of papovavirus from brain tumor and urine of a patient with Wiskott-Aldrich syndrome. J Natl Cancer Inst (1974) 2.00
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther (1994) 1.95
Human interleukin-10 can directly inhibit T-cell growth. Blood (1993) 1.93
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 1.92
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol (1989) 1.86
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome. J Immunol (1970) 1.85
Binding and suppression of the Myc transcriptional activation domain by p107. Science (1994) 1.84
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem (1988) 1.82
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood (1994) 1.79
Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol (1978) 1.79
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med (1978) 1.78
Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood (1997) 1.77
Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol (1985) 1.76
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74
Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood (1997) 1.73
Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood (1991) 1.73
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry (1989) 1.70
Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
A receptor for IgA on human T lymphocytes. J Immunol (1979) 1.65
Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest (1984) 1.63
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61